

# Lei Zheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9174599/publications.pdf>

Version: 2024-02-01

195  
papers

11,481  
citations

41344

49  
h-index

34986

98  
g-index

197  
all docs

197  
docs citations

197  
times ranked

15573  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The tumour microenvironment in pancreatic cancer – clinical challenges and opportunities. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 527-540.   | 27.6 | 590       |
| 2  | STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 283ra52.   | 12.4 | 543       |
| 3  | Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2013, 36, 382-389.  | 2.4  | 460       |
| 4  | Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. <i>Cell Reports</i> , 2017, 19, 203-217.  | 6.4  | 454       |
| 5  | Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. <i>Cancer</i> , 2015, 121, 1128-1137.                                       | 4.1  | 447       |
| 6  | Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 936-945.   | 4.2  | 425       |
| 7  | Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. <i>Cancer Immunology Research</i> , 2014, 2, 616-631.  | 3.4  | 408       |
| 8  | HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 359-366. | 1.6  | 350       |
| 9  | PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. <i>Journal of Immunotherapy</i> , 2015, 38, 1-11.   | 2.4  | 333       |
| 10 | Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. <i>Annals of Surgery</i> , 2019, 270, 340-347.  | 4.2  | 280       |
| 11 | Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2013, 144, 1230-1240.  | 1.3  | 253       |
| 12 | Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.                     | 1.6  | 233       |
| 13 | Lnc RNA acts as a micro RNA sponge and promotes gallbladder tumorigenesis. <i>EMBO Reports</i> , 2017, 18, 1837-1853.  | 4.5  | 202       |
| 14 | Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.  | 17.0 | 202       |
| 15 | Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. <i>OncImmunology</i> , 2015, 4, e1016700.  | 4.6  | 195       |
| 16 | The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 259-265.            | 1.3  | 171       |
| 17 | Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. , 2019, 7, 224.  |      | 154       |
| 18 | Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. <i>PLoS ONE</i> , 2011, 6, e19390.   | 2.5  | 152       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.  | 7.2  | 149       |
| 20 | The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 2352-2358.   | 1.5  | 147       |
| 21 | Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.  | 17.0 | 146       |
| 22 | Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.   | 0.9  | 140       |
| 23 | Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. <i>Annals of Surgery</i> , 2018, 268, 1-8.   | 4.2  | 139       |
| 24 | Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2016, 264, 1073-1081.  | 4.2  | 131       |
| 25 | Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. <i>Journal of Clinical Oncology</i> , 2017, 35, 274-280. | 1.6  | 124       |
| 26 | Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.  | 3.4  | 119       |
| 27 | Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.  | 7.0  | 118       |
| 28 | Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. <i>World Journal of Gastroenterology</i> , 2014, 20, 2237.   | 3.3  | 105       |
| 29 | Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 498-505.                 | 6.4  | 105       |
| 30 | A Preclinical Murine Model of Hepatic Metastases. <i>Journal of Visualized Experiments</i> , 2014, , 51677.   | 0.3  | 95        |
| 31 | Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. <i>Cancer Research</i> , 2016, 76, 5395-5404.  | 0.9  | 95        |
| 32 | Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. <i>Science Signaling</i> , 2015, 8, ra77.  | 3.6  | 89        |
| 33 | Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. <i>Gastroenterology</i> , 2019, 157, 838-850.e6.  | 1.3  | 88        |
| 34 | ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells. <i>Gastroenterology</i> , 2019, 156, 722-734.e6.               | 1.3  | 82        |
| 35 | Current Standards of Chemotherapy for Pancreatic Cancer. <i>Clinical Therapeutics</i> , 2017, 39, 2125-2134.  | 2.5  | 80        |
| 36 | Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 237-243.   | 7.2  | 78        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.   | 2.2 | 75        |
| 38 | Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumorâ€“vessel relationships. <i>Journal of Radiation Oncology</i> , 2013, 2, 413-425.  | 0.7 | 74        |
| 39 | Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.  | 7.0 | 72        |
| 40 | Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. <i>Cancer Research</i> , 2017, 77, 41-52.  | 0.9 | 71        |
| 41 | TGF-Î² blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. <i>Oncotarget</i> , 2015, 6, 43005-43015.   | 1.8 | 68        |
| 42 | A Phase II Study of Allogeneic GM-CSFâ€“Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5129-5139.  | 7.0 | 67        |
| 43 | Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. <i>Cancer Biology and Medicine</i> , 2015, 12, 201-8.   | 3.0 | 67        |
| 44 | The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. <i>Hpb</i> , 2015, 17, 292-298.  | 0.3 | 63        |
| 45 | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44073-44081.   | 1.8 | 63        |
| 46 | Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. <i>Oncotarget</i> , 2015, 6, 36903-36910.  | 1.8 | 62        |
| 47 | Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 196-203.   | 4.1 | 61        |
| 48 | ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. <i>Clinical Cancer Research</i> , 2018, 24, 3186-3196.  | 7.0 | 59        |
| 49 | Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363.  | 7.0 | 57        |
| 50 | Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune â€œDefectsâ€“ in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1472.   | 2.4 | 56        |
| 51 | Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.  | 1.7 | 54        |
| 52 | Managing cardiotoxicity associated with immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 6-14.  | 1.2 | 52        |
| 53 | From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.   | 5.0 | 52        |
| 54 | HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 638-638. | 1.6 | 51        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Vaccine therapy for pancreatic cancer. <i>Oncolmmunology</i> , 2013, 2, e26662.  | 4.6  | 50        |
| 56 | Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 269-280.                 | 2.3  | 50        |
| 57 | A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 1485-1494. | 2.8  | 48        |
| 58 | Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. <i>Cancer Letters</i> , 2017, 406, 22-26.  | 7.2  | 47        |
| 59 | IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 1742-1755.   | 8.2  | 47        |
| 60 | Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. <i>Journal of Surgical Oncology</i> , 2017, 116, 55-62.  | 1.7  | 46        |
| 61 | Anti-pancreatic tumor efficacy of a <i>Listeria</i> -based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. , 2019, 7, 132.   |      | 46        |
| 62 | Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.   |      | 45        |
| 63 | <scp>PAK1</scp> mediates pancreatic cancer cell migration and resistance to <scp>MET</scp> inhibition. <i>Journal of Pathology</i> , 2014, 234, 502-513.   | 4.5  | 44        |
| 64 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 39.   | 3.7  | 44        |
| 65 | PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.  | 6.3  | 43        |
| 66 | Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. , 2018, 6, 118.   |      | 43        |
| 67 | Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 940-953.                                | 10.5 | 41        |
| 68 | E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer. <i>Oncogene</i> , 2019, 38, 1269-1281.   | 5.9  | 40        |
| 69 | Blocking NF- $\kappa$ B Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5939-5950.                             | 7.0  | 39        |
| 70 | Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e962401.   | 4.6  | 37        |
| 71 | Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 6-17.  | 1.2  | 37        |
| 72 | Exome Capture Sequencing of Adenoma Reveals Genetic Alterations in Multiple Cellular Pathways at the Early Stage of Colorectal Tumorigenesis. <i>PLoS ONE</i> , 2013, 8, e53310.                   | 2.5  | 37        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 366.  | 17.1 | 37        |
| 74 | Integration of the metabolic/redox state, histone gene switching, DNA replication and S-phase progression by moonlighting metabolic enzymes. <i>Bioscience Reports</i> , 2013, 33, e00018.  | 2.4  | 36        |
| 75 | Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1805-1815.  | 4.1  | 36        |
| 76 | A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells. <i>Cancer Research</i> , 2019, 79, 2878-2891.  | 0.9  | 36        |
| 77 | A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 257-257. | 1.6  | 36        |
| 78 | Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. <i>Lancet Oncology</i> , The, 2022, 23, e62-e74.   | 10.7 | 36        |
| 79 | Vaccines for Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 642-652.   | 2.0  | 35        |
| 80 | DNA methylation in the tumor microenvironment. <i>Journal of Zhejiang University: Science B</i> , 2017, 18, 365-372.  | 2.8  | 35        |
| 81 | Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. <i>Surgery</i> , 2018, 163, 1090-1096.        | 1.9  | 35        |
| 82 | Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1278-1286.                    | 7.0  | 35        |
| 83 | MicroRNA-320b promotes colorectal cancer proliferation and invasion by competing with its homologous microRNA-320a. <i>Cancer Letters</i> , 2015, 356, 669-675.   | 7.2  | 34        |
| 84 | MicroRNA regulation network in colorectal cancer metastasis. <i>World Journal of Biological Chemistry</i> , 2014, 5, 301.   | 4.3  | 33        |
| 85 | Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique. <i>Journal of Controlled Release</i> , 2016, 223, 11-21.   | 9.9  | 32        |
| 86 | Low Total Lymphocyte Count Is Associated with Poor Survival in Patients with Resected Pancreatic Adenocarcinoma Receiving a GM-CSF Secreting Pancreatic Tumor Vaccine. <i>Annals of Surgical Oncology</i> , 2013, 20, 725-730.  | 1.5  | 31        |
| 87 | Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. <i>Annals of Surgical Oncology</i> , 2018, 25, 280-289.  | 1.5  | 31        |
| 88 | Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve. , 2019, 200, 126-134.   |      | 31        |
| 89 | Combination of coenzyme Q10-loaded liposomes with ultrasound targeted microbubbles destruction (UTMD) for early theranostics of diabetic nephropathy. <i>International Journal of Pharmaceutics</i> , 2017, 528, 664-674.   | 5.2  | 30        |
| 90 | Multidisciplinary Management of Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 265-287.   | 1.5  | 29        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | Precision medicine in pancreatic cancer: treating every patient as an exception. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 805-810.  | 8.1  | 29        |
| 92  | Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. <i>Journal of Visualized Experiments</i> , 2013, , .   | 0.3  | 28        |
| 93  | Small molecule drugs with immunomodulatory effects in cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2463-2468.   | 3.3  | 28        |
| 94  | Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. <i>Oncotarget</i> , 2018, 9, 16427-16436.  | 1.8  | 28        |
| 95  | Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2399-2409.   | 4.1  | 27        |
| 96  | Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7103-7119.  | 6.7  | 27        |
| 97  | Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 112-114.   | 4.6  | 26        |
| 98  | A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyteâ€“Macrophage Colony Stimulating Factorâ€“Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 3931-3937. | 1.5  | 26        |
| 99  | Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 184.   | 17.0 | 26        |
| 100 | Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer. <i>Bioconjugate Chemistry</i> , 2019, 30, 1425-1433.   | 3.6  | 25        |
| 101 | Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 274, 162-169.  | 4.2  | 25        |
| 102 | Microfluidic device for primary tumor spheroid isolation. <i>Experimental Hematology and Oncology</i> , 2017, 6, 22.  | 5.0  | 24        |
| 103 | Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. <i>Journal of Hematology and Oncology</i> , 2022, 15, 37.   | 17.0 | 23        |
| 104 | MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 2117-2131.   | 1.6  | 22        |
| 105 | CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. <i>Cancer Letters</i> , 2021, 499, 99-108.  | 7.2  | 22        |
| 106 | Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. <i>JCI Insight</i> , 2020, 5, .   | 5.0  | 22        |
| 107 | Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 115-25.  | 1.4  | 22        |
| 108 | CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. <i>Journal of Experimental Medicine</i> , 2022, 219, .   | 8.5  | 22        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Solitary splenic tuberculosis: a case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2016, 14, 154.  | 1.9 | 21        |
| 110 | Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 225-233.  | 3.4 | 21        |
| 111 | Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. <i>Modern Pathology</i> , 2019, 32, 1806-1813.  | 5.5 | 21        |
| 112 | Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 16362-16371.  | 1.8 | 21        |
| 113 | BEX1 Promotes Imatinib-Induced Apoptosis by Binding to and Antagonizing BCL-2. <i>PLoS ONE</i> , 2014, 9, e91782.  | 2.5 | 20        |
| 114 | Intrarenal delivery of bFGF-loaded liposome under guiding of ultrasound-targeted microbubble destruction prevent diabetic nephropathy through inhibition of inflammation. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 373-385. | 2.8 | 20        |
| 115 | Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 417-424.                              | 2.1 | 19        |
| 116 | Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.  | 2.8 | 19        |
| 117 | Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.   | 6.8 | 18        |
| 118 | Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 206-214.  | 3.0 | 18        |
| 119 | Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1069-1076.                                 | 1.0 | 17        |
| 120 | Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. , 2020, 8, e000351.   |     | 17        |
| 121 | Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 7-7.   | 1.2 | 17        |
| 122 | Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 439-439.                              | 1.6 | 17        |
| 123 | Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 269-269.  | 1.6 | 15        |
| 124 | Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 106405-106414.  | 1.8 | 14        |
| 125 | Interaction of Heat Shock Protein Cpn10 with the Cyclin E/Cdk2 Substrate Nuclear Protein Ataxia-Telangiectasia (NPAT) Is Involved in Regulating Histone Transcription. <i>Journal of Biological Chemistry</i> , 2015, 290, 29290-29300.                | 3.4 | 13        |
| 126 | Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. <i>Cancer Letters</i> , 2022, 526, 155-167.   | 7.2 | 13        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 31-31.  | 1.2 | 12        |
| 128 | Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. <i>Annals of Surgical Oncology</i> , 2022, 29, 2456-2468. | 1.5 | 12        |
| 129 | Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. <i>Cancer Letters</i> , 2022, 539, 215722.   | 7.2 | 12        |
| 130 | Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy. <i>International Journal of Nanomedicine</i> , 2016, 11, 675.   | 6.7 | 11        |
| 131 | Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. <i>Radiation Oncology</i> , 2016, 11, 138.   | 2.7 | 11        |
| 132 | Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.   | 0.5 | 11        |
| 133 | A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021, 13, 25.  | 4.1 | 11        |
| 134 | Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 401-414.   | 1.5 | 11        |
| 135 | High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. <i>Cancer Medicine</i> , 2022, , .   | 2.8 | 11        |
| 136 | Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. <i>Immunotherapy</i> , 2014, 6, 1017-1020.  | 2.0 | 10        |
| 137 | Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. <i>Cancer Letters</i> , 2021, 497, 221-228.  | 7.2 | 10        |
| 138 | Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>Oncolmmunology</i> , 2021, 10, 2001159.   | 4.6 | 10        |
| 139 | Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2. <i>Cell Adhesion and Migration</i> , 2017, 11, 514-523.   | 2.7 | 9         |
| 140 | Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?. <i>Cancer Biology and Therapy</i> , 2015, 16, 360-362.   | 3.4 | 8         |
| 141 | New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.  | 3.2 | 8         |
| 142 | Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. <i>Clinical Cancer Research</i> , 2021, 27, 3825-3833.   | 7.0 | 8         |
| 143 | Patient- versus physician-reported outcomes in patients enrolled in a prospective study involving stereotactic body radiation therapy in unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 84-84.  | 1.6 | 8         |
| 144 | Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2019, 2, 21-21.   | 1.2 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | A hemi-spleen injection model of liver metastasis for prostate cancer. <i>Prostate</i> , 2020, 80, 1263-1269.   | 2.3 | 7         |
| 146 | NF- $\kappa$ B p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. , 2020, 8, e000244.   |     | 7         |
| 147 | An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2020, 11, 1929-1941.   | 1.8 | 7         |
| 148 | Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.  | 1.6 | 7         |
| 149 | Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. <i>Radiation Oncology</i> , 2021, 16, 242.  | 2.7 | 7         |
| 150 | New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification [ ]. <i>Cancer Letters</i> , 2021, 518, 207-213.  | 7.2 | 6         |
| 151 | Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 591-591.   | 1.6 | 6         |
| 152 | High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 368-379.                     | 1.4 | 6         |
| 153 | Gemcitabine and XCT790, an ERK1/2 inverse agonist, display a synergistic anticancer effect in pancreatic cancer. <i>International Journal of Medical Sciences</i> , 2022, 19, 286-298.  | 2.5 | 6         |
| 154 | Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. <i>Radiation Oncology Journal</i> , 2021, 39, 304-314. | 1.5 | 6         |
| 155 | Immune defects in pancreatic cancer. <i>Annals of Pancreatic Cancer</i> , 2018, 1, 33-33.   | 1.2 | 5         |
| 156 | A phase I open label study evaluating VT1021 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3158-TPS3158.  | 1.6 | 5         |
| 157 | A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair-proficient (MMR-p) advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 563-563.  | 1.6 | 5         |
| 158 | Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. <i>Practical Radiation Oncology</i> , 2022, 12, 511-523.   | 2.1 | 5         |
| 159 | Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 441-448.   | 1.4 | 4         |
| 160 | Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3128-TPS3128.  | 1.6 | 4         |
| 161 | Stereotactic body radiation therapy for pancreatic cancer: Single institutional experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 328-328.   | 1.6 | 4         |
| 162 | In vivo bioluminescence tomography-guided radiation research platform for pancreatic cancer: an initial study using subcutaneous and orthotopic pancreatic tumor models. , 2020, 11224, .   |     | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. <i>Seminars in Oncology</i> , 2014, 41, 559-575.  | 2.2 | 3         |
| 164 | Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2578-2578.  | 1.6 | 3         |
| 165 | Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors. <i>Hpb</i> , 2022, 24, 681-690.   | 0.3 | 3         |
| 166 | Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 486-489.                          | 0.8 | 2         |
| 167 | Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2353-2362.   | 4.1 | 2         |
| 168 | A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4160-TPS4160.  | 1.6 | 2         |
| 169 | Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4127-4127.  | 1.6 | 2         |
| 170 | Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature. <i>Current Oncology</i> , 2022, 29, 308-320.   | 2.2 | 2         |
| 171 | Overcoming immune system evasion by personalized immunotherapy. <i>Personalized Medicine</i> , 2014, 11, 561-564.   | 1.5 | 1         |
| 172 | Drug-Coated Balloon versus Bare Nitinol Stent in Femoropopliteal Artery: 12 Months Outcome from a Single Center in China. <i>Annals of Vascular Surgery</i> , 2021, 74, 367-381.  | 0.9 | 1         |
| 173 | ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 714-715.   | 1.5 | 1         |
| 174 | Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. <i>Journal of Clinical Oncology</i> , 2013, 31, 4057-4057.   | 1.6 | 1         |
| 175 | The significance of ascites in patients with pancreatic cancer: A case-control study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 445-445.   | 1.6 | 1         |
| 176 | Targeting Sema3D in pancreatic cancer: A novel therapeutic strategy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4129-4129.  | 1.6 | 1         |
| 177 | Stereotactic body radiation therapy and patient-reported quality of life prospectively evaluated in patients with unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 92-92.  | 1.6 | 1         |
| 178 | The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. <i>Current Problems in Diagnostic Radiology</i> , 2022, , .  | 1.4 | 1         |
| 179 | RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, , .   | 3.0 | 1         |
| 180 | Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4192-TPS4192. | 1.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.   |     | 0         |
| 182 | Nonselective $\beta$ -adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 8-8.  | 1.2 | 0         |
| 183 | Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2021, 50, 64-70.  | 1.1 | 0         |
| 184 | Lipid and neutrophil accumulation and active inflammasome in high BMI tumor regions of human pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16271-e16271.  | 1.6 | 0         |
| 185 | Long-term outcomes of a prospective single institution study with multiagent chemotherapy and stereotactic body radiation therapy in locally advanced or recurrent pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 440-440. | 1.6 | 0         |
| 186 | Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 285-285.   | 1.6 | 0         |
| 187 | A phase 2 trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4135-4135.                         | 1.6 | 0         |
| 188 | Impact of stereotactic body radiation therapy on patient-reported quality of life in patients with unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 413-413.   | 1.6 | 0         |
| 189 | A prospective study evaluating stereotactic body radiation therapy in unresectable, recurrent, or residual pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 454-454.   | 1.6 | 0         |
| 190 | Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3626-TPS3626.  | 1.6 | 0         |
| 191 | Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.  |     | 0         |
| 192 | Preface: pancreas adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 23-23.  | 1.2 | 0         |
| 193 | Preface for Special Edition Pancreas Cancer. <i>Chinese Clinical Oncology</i> , 2017, 6, 57-57.   | 1.2 | 0         |
| 194 | Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 532-532.  | 1.6 | 0         |
| 195 | Targeting MEN1-deficient tumors with DHODH inhibitor. <i>Journal of the National Cancer Center</i> , 2022, , .  | 7.4 | 0         |